✦ LIBER ✦

Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy

✍ Scribed by S. Jolles; E. Bernatowska; J. de Gracia; M. Borte; V. Cristea; H.H. Peter; B.H. Belohradsky; V. Wahn; J. Neufang-Hüber; O. Zenker; B. Grimbacher

Book ID: 113542004
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 506 KB
Volume: 141
Category: Article
ISSN: 1090-2341
DOI: 10.1016/j.clim.2011.06.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluation of safety and efficacy of a 2

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients

✍ Adriana Martin, Robert Schellenberg 📂 Article 📅 2012 🏛 BC Decker 🌐 English ⚖ 68 KB

Efficacy and Safety of IgPro20, a 20% Im

Efficacy and Safety of IgPro20, a 20% Immunoglobulin for Subcutaneous Administration, in Patients with Primary Immunodeficiency Switching from Intravenous Replacement Therapy

✍ Stephen Jolles; Victor Cristea; Volker Wahn; Marianne Debré; Hilary Longhurst; O 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Efficacy and safety of home-based subcut

Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies

✍ M. Borte; E. Bernatowska; H. D. Ochs; C. M. Roifman; the Vivaglobin Study Group 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 253 KB

Efficacy and Safety of Hizentra®, a New

Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

✍ Michael Borte; Malgorzata Pac; Margit Serban; Teresa Gonzalez-Quevedo; Bodo Grim 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 182 KB

Efficacy and Safety of Subcutaneous Viva

Efficacy and Safety of Subcutaneous Vivaglobin® Replacement Therapy in Previously Untreated Patients with Primary Immunodeficiency: A Prospective, Multicenter Study

✍ Michael Borte; Isabella Quinti; Annarosa Soresina; Eduardo Fernández-Cruz; Bruce 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 261 KB

Patients with primary immunodeficiency r

Patients with primary immunodeficiency receiving subcutaneous immune globulin Hizentra maintain health-related quality of life and treatment satisfaction in a multicentre extension study of efficacy, tolerability and safety

✍ Christopher A. Jones; Mikhail Rojavin; Jeffrey S. Baggish 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB